Swedish Orphan Biovitrum

SOBI · Nasdaq Stockholm · SEK

kr 427.80−1.52%−kr 6.60

Close · October 2, 2026

At a glance

Revenue growth
+8.50%
2025 vs 2024
Net income growth
−87.70%
2025 vs 2024
Net margin
1.7%
2024: 14.9%

Financial data

Amounts in millions of SEK; per-share values in SEK; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue7,8427,1847,8217,7766,1756,4657,4356,8945,4426,2566,8435,168
Cost of revenue1,8291,7041,5141,5621,3941,4971,6311,2901,2751,5211,3671,135
Gross profit6,0135,4806,3076,2144,7814,9685,8045,6044,1674,7355,4764,033
Selling, general and administrative2,8942,6212,9292,6292,7352,6793,1892,6942,6292,4542,9472,578
Research and development1,130948879754783834981845898805792761
Operating income1,9811,9102,5562,8051,2471,4491,6332,0806431,4681,859649
EBIT1,9811,9102,5562,8051,2471,4491,6332,0806431,4681,859649
EBITDA2,7852,6923,1303,7082,1362,3872,3453,0041,5582,3772,5061,585
Interest expense204173156168216262245326337331372431
Pre-tax income1,4131,6812,172-4,0267941,0961,4381,7122759821,238116
Income tax315363310-1,13216022147.024851.018221222.0
Net income1,0971,3181,862-2,8946368751,3971,4642248001,02694.0
Net income to common shareholders1,0971,3181,862-2,8946368751,3971,4642248001,02694.0
Basic EPS3.173.815.39-8.401.852.554.074.270.662.353.020.30
Diluted EPS3.143.775.34-8.401.832.524.024.220.652.332.990.30
Average shares (basic)346346345345344343343343341340340316
Average shares (diluted)350349349345347347347347345344343319